Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
$0.10
+5.5%
$0.15
$0.09
$1.25
$4.40M-0.244.54 million shs4.34 million shs
Cerecor Inc. stock logo
CERC
Cerecor
$14.20
+9.2%
$2.60
$1.98
$4.50
$1.36B1.441.27 million shs37,075 shs
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$0.02
+3.4%
$0.02
$0.01
$3.75
$831K-1.12781,909 shs161,657 shs
LifeVantage Co. stock logo
LFVN
LifeVantage
$6.26
+1.5%
$6.59
$3.04
$8.69
$80.57M0.7834,304 shs3,545 shs
Veru Inc. stock logo
VERU
Veru
$1.28
-3.4%
$0.81
$0.36
$1.92
$186.63M-0.212.36 million shs1.40 million shs
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
-29.63%-30.20%-39.16%-33.31%-89.63%
Cerecor Inc. stock logo
CERC
Cerecor
0.00%-18.44%+166.39%+217.07%+320.71%
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
+16.04%+9.56%-22.56%-50.00%-99.43%
LifeVantage Co. stock logo
LFVN
LifeVantage
-3.67%-6.52%-1.59%+7.12%+83.23%
Veru Inc. stock logo
VERU
Veru
+3.53%+13.79%+116.68%+199.80%+2.72%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
0.771 of 5 stars
0.05.00.04.61.40.00.0
Cerecor Inc. stock logo
CERC
Cerecor
N/AN/AN/AN/AN/AN/AN/AN/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
1.9373 of 5 stars
0.03.01.72.72.51.71.3
Veru Inc. stock logo
VERU
Veru
1.3001 of 5 stars
3.41.00.00.02.91.70.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
3.00
BuyN/AN/A
Cerecor Inc. stock logo
CERC
Cerecor
N/AN/AN/AN/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
2.00
HoldN/AN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
N/AN/AN/AN/A
Veru Inc. stock logo
VERU
Veru
2.75
Moderate Buy$3.33161.44% Upside

Current Analyst Ratings

Latest CERC, ATXI, EVFM, VERU, and LFVN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/15/2024
Veru Inc. stock logo
VERU
Veru
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$7.00 ➝ $5.00
3/28/2024
Veru Inc. stock logo
VERU
Veru
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$3.00
2/8/2024
Veru Inc. stock logo
VERU
Veru
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$2.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/AN/AN/AN/A$0.03 per shareN/A
Cerecor Inc. stock logo
CERC
Cerecor
$6.70M203.48N/AN/A$0.22 per share64.55
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$18.22M0.05$1.54 per share0.01($2.64) per share-0.01
LifeVantage Co. stock logo
LFVN
LifeVantage
$213.40M0.38$0.51 per share12.35$2.71 per share2.31
Veru Inc. stock logo
VERU
Veru
$16.30M11.45N/AN/A$0.22 per share5.80

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
-$10.38M-$1.27N/AN/AN/AN/A-335.11%5/10/2024 (Estimated)
Cerecor Inc. stock logo
CERC
Cerecor
-$63.50M-$0.57N/AN/AN/A-1,194.82%-261.82%-133.96%N/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$52.98M-$7.62N/AN/A290.81%-90.20%331.20%4/26/2024 (Estimated)
LifeVantage Co. stock logo
LFVN
LifeVantage
$2.54M$0.2327.22N/A1.40%19.96%9.48%5/2/2024 (Confirmed)
Veru Inc. stock logo
VERU
Veru
-$93.15M-$0.75N/AN/AN/A-405.04%-257.92%-107.27%5/9/2024 (Estimated)

Latest CERC, ATXI, EVFM, VERU, and LFVN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024N/A
LifeVantage Co. stock logo
LFVN
LifeVantage
N/AN/AN/AN/AN/AN/A  
4/1/2024Q1 2024
Veru Inc. stock logo
VERU
Veru
N/A-$0.09-$0.09-$0.10N/A$2.14 million
3/27/2024Q4 2023
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/A-$0.44-$0.44-$0.44N/A$4.84 million
3/18/2024Q4 2023
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/A$0.56+$0.56$0.56N/AN/A
1/30/2024Q2 2024
LifeVantage Co. stock logo
LFVN
LifeVantage
N/A$0.10+$0.10$0.25N/A$51.62 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/AN/AN/AN/AN/A
Cerecor Inc. stock logo
CERC
Cerecor
N/AN/AN/AN/AN/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/AN/AN/AN/AN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.142.24%N/A60.87%1 Years
Veru Inc. stock logo
VERU
Veru
N/AN/AN/AN/AN/A

Latest CERC, ATXI, EVFM, VERU, and LFVN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/25/2024
LifeVantage Co. stock logo
LFVN
LifeVantage
Quarterly$0.03502.64%2/29/20243/1/20243/15/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/A
1.55
1.55
Cerecor Inc. stock logo
CERC
Cerecor
0.79
2.19
2.18
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/A
0.13
0.10
LifeVantage Co. stock logo
LFVN
LifeVantage
N/A
1.68
1.03
Veru Inc. stock logo
VERU
Veru
N/A
3.21
2.79

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
17.34%
Cerecor Inc. stock logo
CERC
Cerecor
62.84%
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.22%
LifeVantage Co. stock logo
LFVN
LifeVantage
35.32%
Veru Inc. stock logo
VERU
Veru
47.16%

Insider Ownership

CompanyInsider Ownership
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
1.80%
Cerecor Inc. stock logo
CERC
Cerecor
45.70%
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.21%
LifeVantage Co. stock logo
LFVN
LifeVantage
6.76%
Veru Inc. stock logo
VERU
Veru
14.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
344.26 million43.46 millionNot Optionable
Cerecor Inc. stock logo
CERC
Cerecor
3196.01 millionN/ANot Optionable
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
3753.96 million53.85 millionNot Optionable
LifeVantage Co. stock logo
LFVN
LifeVantage
24812.87 million12.00 millionOptionable
Veru Inc. stock logo
VERU
Veru
189146.38 million125.60 millionOptionable

CERC, ATXI, EVFM, VERU, and LFVN Headlines

SourceHeadline
Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11
globenewswire.com - April 25 at 8:30 AM
Netflix To Stop Sharing Subscriber Data; Stock DipsNetflix To Stop Sharing Subscriber Data; Stock Dips
markets.businessinsider.com - April 19 at 6:13 PM
What Makes Veru (VERU) a New Buy StockWhat Makes Veru (VERU) a New Buy Stock
zacks.com - April 17 at 1:01 PM
Veru (NASDAQ:VERU) Given "Outperform" Rating at OppenheimerVeru (NASDAQ:VERU) Given "Outperform" Rating at Oppenheimer
americanbankingnews.com - April 16 at 3:26 AM
Veru (NASDAQ:VERU) Earns "Outperform" Rating from OppenheimerVeru (NASDAQ:VERU) Earns "Outperform" Rating from Oppenheimer
marketbeat.com - April 15 at 8:29 AM
REVEALED: Transport Malta officials at centre of maritime fines corruption racketREVEALED: Transport Malta officials at centre of maritime fines corruption racket
maltatoday.com.mt - April 2 at 12:43 AM
Veru Announces Date of 2024 Annual Meeting of ShareholdersVeru Announces Date of 2024 Annual Meeting of Shareholders
finance.yahoo.com - April 1 at 7:43 PM
Flag carrier Air Malta ceases operations today, its 50th birthdayFlag carrier Air Malta ceases operations today, its 50th birthday
maltatoday.com.mt - March 31 at 6:39 PM
Veru IncVeru Inc
morningstar.com - March 29 at 9:35 PM
Updated | Mosta trees vandalised: ERA, police investigatingUpdated | Mosta trees vandalised: ERA, police investigating
maltatoday.com.mt - March 29 at 8:54 AM
Raymond James Begins Coverage on Veru (NASDAQ:VERU)Raymond James Begins Coverage on Veru (NASDAQ:VERU)
marketbeat.com - March 28 at 8:28 AM
R&B Realty’s Gateway at Wynwood hit with foreclosure lawsuitR&B Realty’s Gateway at Wynwood hit with foreclosure lawsuit
therealdeal.com - March 22 at 6:18 PM
Veru Reschedules Annual Meeting of ShareholdersVeru Reschedules Annual Meeting of Shareholders
globenewswire.com - March 22 at 4:05 PM
Wynwood offices targeted in $102M foreclosureWynwood offices targeted in $102M foreclosure
bizjournals.com - March 21 at 6:43 PM
Naksha Saran plays a bike taxi driver in her next filmNaksha Saran plays a bike taxi driver in her next film
msn.com - March 19 at 4:27 AM
Precise and efficient cutting (sawing) of lightweight core materialsPrecise and efficient cutting (sawing) of lightweight core materials
jeccomposites.com - March 18 at 1:24 PM
VERU Mar 2024 0.500 putVERU Mar 2024 0.500 put
ca.finance.yahoo.com - March 16 at 1:30 PM
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight LossVeru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
globenewswire.com - March 12 at 8:00 AM
VERU Mar 2024 1.500 putVERU Mar 2024 1.500 put
finance.yahoo.com - March 11 at 11:33 PM
Brussels is mixed bag of emotions on possible Joseph Muscat returnBrussels is mixed bag of emotions on possible Joseph Muscat return
maltatoday.com.mt - March 11 at 1:32 PM
VERU Jan 2025 17.000 callVERU Jan 2025 17.000 call
finance.yahoo.com - March 9 at 6:52 PM
VERU Mar 2024 0.500 callVERU Mar 2024 0.500 call
finance.yahoo.com - March 9 at 1:52 PM
VERU Mar 2024 3.000 putVERU Mar 2024 3.000 put
finance.yahoo.com - March 9 at 1:52 PM
VERU Mar 2024 2.500 putVERU Mar 2024 2.500 put
finance.yahoo.com - March 1 at 11:31 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Avenue Therapeutics logo

Avenue Therapeutics

NASDAQ:ATXI
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.
Cerecor logo

Cerecor

NASDAQ:CERC
Cerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.
Evofem Biosciences logo

Evofem Biosciences

NASDAQ:EVFM
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
LifeVantage logo

LifeVantage

NASDAQ:LFVN
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.
Veru logo

Veru

NASDAQ:VERU
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.